A61P 7 - Drugs for disorders of the blood or the extracellular fluid

Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
12/2001
12/20/2001	WO2001095892A1 Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
12/20/2001	WO2001095785A2 Modulation of immune response and methods based thereon
12/20/2001	WO2001062245A3 Bilirubin or biliverdin degradation fragments
12/20/2001	WO2001049689A3 NOVEL SUBSTITUTED PYRAZOLO[4,3-e]DIAZEPINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, USE AS MEDICINAL PRODUCTS AND PROCESSES FOR PREPARING THEM
12/20/2001	WO2001022969A3 Vasopressin agonist formulation and process
12/20/2001	WO2001016108A3 Bicyclic androgen and progesterone receptor modulator compounds and methods
12/20/2001	US20010053853 Alkanoic acid derivative; integrin receptor antagonist
12/20/2001	US20010053363 Novel amphipathic aldehydes and their uses as adjuvants and immunoeffectors
12/20/2001	US20010053351 Inhibition of GSK-3 beta
12/20/2001	DE10029015A1 Coagulation Factor Xa inhibitor, useful for treatment, prophylaxis or diagnosis of thromboembolic disease, comprising acylated 3- or 4-amidino-benzylamine derivative
12/20/2001	DE10028402A1 New pyridinylamino-alkanoyl-glycyl-beta-alanine derivatives, are integrin inhibitors useful for treating, e.g. thrombosis, cardiac infarction, coronary heart disease, inflammation, tumors, osteoporosis or restenosis
12/20/2001	DE10027383A1 Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz Nucleic acid molecule comprising a sequence coding for a chemokine, a neuropeptide precursor or at least one neuropeptide nucleic acid sequence
12/20/2001	CA2412979A1 Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
12/20/2001	CA2412665A1 Scramblase 2
12/20/2001	CA2412632A1 Hmg-coa reductase inhibitors and method
12/20/2001	CA2412216A1 Lactam inhibitors of factor xa and method
12/20/2001	CA2411962A1 Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion
12/20/2001	CA2411805A1 Serine protease inhibitors
12/20/2001	CA2411798A1 Serine protease inhibitors
12/20/2001	CA2410610A1 Human kinases
12/20/2001	CA2410228A1 A combination product comprising melagatran and a factor viia inhibitor
12/20/2001	CA2410100A1 A combination product comprising melagatran and a factor xa inhibitor
12/20/2001	CA2409315A1 Protein phosphatases
12/20/2001	CA2407699A1 Use of an aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects
12/19/2001	EP1163356A1 Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites
12/19/2001	EP1163332A1 48 human secreted proteins
12/19/2001	EP1163331A1 50 human secreted proteins
12/19/2001	EP1163267A1 47 human secreted proteins
12/19/2001	EP1163255A1 50 human secreted proteins
12/19/2001	EP1163243A2 Calanolides for inhibiting btk
12/19/2001	EP1163236A1 Aromatic heterocyclic compounds as anti-inflammatory agents
12/19/2001	EP1163213A1 Hydroxamic and carboxylic acid derivatives
12/19/2001	EP1163212A1 Amide derivatives
12/19/2001	EP1163208A2 Caspase inhibitors and uses thereof
12/19/2001	EP1163010A1 Hemoglobin-antioxidant conjugates
12/19/2001	EP1162970A2 Anti-inflammatory uses of manzamines
12/19/2001	EP1162884A1 Oral low dose butyrate compositions
12/19/2001	EP0751785B2 Combinations of thrombolytically active proteins and anticoagulants, and uses thereof
12/19/2001	CN1327389A Coupling factor 6 inhibitor and potentiator and use thereof
12/19/2001	CN1327382A Improved formulation for topical non-invasive application in vivo
12/19/2001	CN1326734A Thrombolytic injection for curing cerebral infarction or cerebral thrombus
12/19/2001	CN1076356C Protein having TPO activity
12/19/2001	CN1076353C Alkyl boronic acid derivatives, process for their preparation and pharmaceutical compositions containing them
12/18/2001	US6331615 Nucleic acid molecule encoding heavy or light chain of an antibody which specifically recognizes a protein specifically recognized by monoclonal antibody 5c8 (anti-CD40 ligand)
12/18/2001	US6331556 Benzofuran-4-carboxylic acid amide derivatives used as phosphodiesterase iv or tumor necrosis factor inhibitors
12/18/2001	US6331433 Human T cell leukemia cell line designated D1.1
12/18/2001	CA2213815C Pyrrolidinyl hydroxamic acid compounds and their production process
12/18/2001	CA2209298C Mpl ligand analogs
12/13/2001	WO2001094952A2 Methods and compositions for modulating oxidized ldl transport
12/13/2001	WO2001094613A2 Methods and compounds for influencing beta3 integrin-dependent intracellular processes
12/13/2001	WO2001094555A1 Method for obtaining characterised muscle-derived cell populations and uses
12/13/2001	WO2001094420A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
12/13/2001	WO2001094415A2 Nuclear hormone receptor
12/13/2001	WO2001094413A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation
12/13/2001	WO2001094411A1 Peptides modulating protease activated receptors and methods of using same
12/13/2001	WO2001094391A2 Intracellular signaling proteins
12/13/2001	WO2001094351A1 Caspase inhibitors and uses thereof
12/13/2001	WO2001094347A1 Tetracyclic diketopiperazine compounds as pdev inhibitors
12/13/2001	WO2001094335A2 Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor
12/13/2001	WO2001094333A2 Process for the preparation of benzoyl substituted bicyclic compounds and chiral benzopyran derivatives
12/13/2001	WO2001094330A2 Methods for producing amino substituted chromanes
12/13/2001	WO2001094301A2 Factor viia inhibitory (thio)urea derivatives, their preparation and their use
12/13/2001	WO2001094299A1 Benzene derivatives
12/13/2001	WO2001093914A2 Multivalent platform molecules comprising high molecular weight polyethylene oxide
12/13/2001	WO2001093900A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
12/13/2001	WO2001093893A2 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
12/13/2001	WO2001093885A1 Therapeutic agents - ii
12/13/2001	WO2001093884A1 Therapeutic agents - i
12/13/2001	WO2001093883A1 Therapeutic agents - iii
12/13/2001	WO2001093871A1 Reangiostenosis preventives
12/13/2001	WO2001093870A1 Remedies for diseases caused by fibrin formation and/or endothelial cell damage
12/13/2001	WO2001093845A2 Carboxyalkylether-acat inhibitor combinations
12/13/2001	WO2001093836A2 Encapsulation of polynucleotides and drugs into targeted liposomes
12/13/2001	WO2001070968A3 Production of recombinant blood clotting factors in human cell lines
12/13/2001	WO2001068147A3 Synthetic oligonucleotides as inducers of erythroid differentiation
12/13/2001	WO2001044445A3 Human lyases and associated proteins
12/13/2001	WO2001042262A3 Antithrombotic compound
12/13/2001	WO2001026637A3 Transdermal therapeutic system for administering acetylsalicylic acid and/or salicylic acid
12/13/2001	US20010051595 Injection into blood
12/13/2001	CA2810249A1 Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury
12/13/2001	CA2414076A1 Multivalent platform molecules comprising high molecular weight polyethylene oxide
12/13/2001	CA2413906A1 Carboxyalkylether-acat inhibitor combinations
12/13/2001	CA2412436A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
12/13/2001	CA2412377A1 B7-related nucleic acids and polypeptides and their uses for immunomodulation
12/13/2001	CA2411762A1 Method for obtaining characterised muscle-derived cell populations and uses
12/13/2001	CA2411596A1 Therapeutic agents - ii
12/13/2001	CA2411542A1 Encapsulation of polynucleotides and drugs into targeted liposomes
12/13/2001	CA2411010A1 Tetracyclic diketopiperazine compounds as pdev inhibitors
12/13/2001	CA2409392A1 Intracellular signaling proteins
12/13/2001	CA2409197A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
12/13/2001	CA2409015A1 Caspase inhibitors and uses thereof
12/13/2001	CA2408748A1 Nuclear hormone receptor
12/13/2001	CA2398277A1 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for protecting cns cells from glutamate toxicity
12/13/2001	CA2381249A1 Methods and compositions for modulating oxidized ldl transport
12/12/2001	EP1162458A1 Methods and compositions for modulating oxidized LDL transport
12/12/2001	EP1162194A1 Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
12/12/2001	EP1161948A2 Pharmaceutical or food composition for treatment of brain edema
12/12/2001	EP1161549A2 Retrovirus producing cells utilizing a high multiplicity of transduction
12/12/2001	EP1161530A1 Protein for blocking platelet adhesion
12/12/2001	EP1161444A1 A novel inhibitor of programmed cell death

1 ... 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 ... 671